

Supplemental Table 1 Dynamic change trend of HBV viral load

Month	0	3	6	9	12	15	18	21	24
NAFLD (n=40)	8.1±0.5	4.0±1.1	3.5±0.8	3.1±0.9	2.9±0.9	2.8±1.4	2.7±1.2	2.5±1.7	2.9±1.8
Non-NAFLD (n=80)	8.0±0.5	3.8±1.2	3.1±1.3	2.7±1.1	2.4±1.0	2.1±0.8	2.1±1.0	1.8±0.6	2.0±0.9
t	0.2829	1.011	1.676	2.101	2.511	2.851	2.104	2.505	2.503
P	0.7777	0.3145	0.0969	0.0382	0.0137	0.0056	0.0392	0.0152	0.0151

Note: Values were expressed as n (%). NAFLD, Nonalcoholic fatty liver disease; CHB, chronic hepatitis B; HBV, hepatitis B virus; HBV DNA, hepatitis B virus deoxyribonucleic acid.

Supplemental Table 2 Cumulative negative conversion rate of HBV.

Month	0	3	6	9	12	15	18	21	24
NAFLD	0	0	0	2	5	10	16	21	25
(n=40)	(0%)	(0%)	(0%)	(5.0%)	(12.5%)	(25.0%)	(40.0%)	(52.5%)	(62.5%)
Non-NAFLD	0	2	8	15	30	42	51	63	69
(n=80)	(0%)	(2.5%)	(10%)	(18.8%)	(37.5%)	(52.5%)	(63.8%)	(78.8%)	(86.3%)
<i>P</i>		0.552	0.051	0.042	0.005	0.004	0.014	0.003	0.003

Note: Values were expressed as n (%). NAFLD, Nonalcoholic fatty liver disease; CHB, chronic hepatitis B; HBV, hepatitis B virus. .

Supplemental Table 3 Biochemical response of CHB patients with and without NAFLD by antiviral therapy at 24 months. Normalization rate of ALT (≤ 30 U/L and ≤ 19 U/L for males and females);

Month	0	3	6	9	12	15	18	21	24
NAFLD	0	11	15	18	22	25	27	31	32
(n=38)	(0%)	(29.0%)	(39.5%)	(47.4%)	(57.9%)	(65.8%)	(71.1%)	(81.6%)	(84.2%)
Non-NAFLD	0	19	31	45	53	56	60	61	65
(n=70)	(0%)	(27.1%)	(44.3%)	(64.3%)	(75.7%)	(80.0%)	(85.7%)	(87.1%)	(92.9%)
<i>p</i>		0.842	0.629	0.089	0.055	0.103	0.066	0.437	0.156

Note: Values were expressed as n (%). NAFLD, Nonalcoholic fatty liver disease; CHB, chronic hepatitis B; ALT, Alanine aminotransferase.

Supplemental Table 4 Biochemical response of CHB patients with and without NAFLD by antiviral therapy at 24 months. Normalization rate of AST (≤ 40 U/L for males and females).

Month	0	3	6	9	12	15	18	21	24
NAFLD	0	5(26.3%)	12	14	15	17	17	18	18
(n=19)	(0%)		(63.2%)	(73.7%)	(79.0%)	(89.5%)	(89.5%)	(94.7%)	(94.7%)
Non-NAFLD	0	26	39	43	49	50	50	50	50
(n=51)	(0%)	(51.0%)	(76.5%)	(84.3%)	(96.1%)	(98.0%)	(98.0%)	(98.0%)	(98.0%)
p		0.065	0.265	0.309	0.042	0.177	0.177	0.472	0.472

Note: Values were expressed as n (%). NAFLD, Nonalcoholic fatty liver disease; CHB, chronic hepatitis B; AST, Aspartate aminotransferase.

Supplemental Table 5 Virological response of CHB patients with and without NAFLD at different antiviral treatment duration. Cumulative negative conversion rate of HBV low viral load.

Month	0	3	6	9	12	15	18	21	24
NAFLD	0	33	42	45	51	53	55	56	57
(n=58)	(0%)	(56.9%)	(72.4%)	(77.6%)	(87.9%)	(91.4%)	(94.8%)	(96.6%)	(98.3%)
Non-NAFLD	0	52	59	64	66	67	67	68	68
(n=68)	(0%)	(76.5%)	(86.8%)	(94.1%)	(97.1%)	(98.5%)	(98.5%)	(100%)	(100%)
P		0.019	0.044	0.009	0.079	0.094	0.333	0.210	0.460

Note: Values were expressed as n (%). NAFLD, Nonalcoholic fatty liver disease; CHB, chronic hepatitis B; HBV, hepatitis B virus;